Form 4: Surmodics CFO Arens Reports Post-Merger Equity Changes

Surmodics Chief Financial Officer Timothy J. Arens reported the disposition of all common stock and conversion of stock options into cash following the company's merger into a wholly-owned subsidiary of BCE Parent, LLC.

Summary

• Surmodics, Inc. merged with BCE Merger Sub, Inc., resulting in Surmodics, Inc. becoming a wholly-owned subsidiary of BCE Parent, LLC, as per a Merger Agreement dated May 28, 2024.
• Each outstanding share of Surmodics common stock was automatically cancelled and converted into the right to receive $43.00 per share in cash, without interest and subject to tax withholdings.
• Timothy J. Arens, Chief Financial Officer, disposed of 67,299 shares of common stock as a result of the merger.
• All outstanding restricted stock units (RSUs) held by Mr. Arens vested immediately prior to the merger's effective time and were converted into the $43.00 per share cash consideration.
• All unexercised stock options held by Mr. Arens were cancelled and automatically converted into a cash payment equal to the product of the aggregate number of shares subject to the option and the excess, if any, of the $43.00 merger consideration over the option's applicable per share exercise price, subject to tax withholdings.
• Following the merger, Mr. Arens no longer beneficially owns, directly or indirectly, any shares of Surmodics Common Stock.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger where shareholders received a definitive cash payout of $43.00 per share, which is generally a positive outcome for investors holding the stock prior to the merger. Equity compensation for the CFO was also converted to cash.

Positives

• Shareholders, including the reporting person, received a definitive cash payment of $43.00 per share for their common stock.
• Restricted stock units (RSUs) held by the reporting person vested immediately prior to the merger, converting into the cash merger consideration.
• In-the-money stock options held by the reporting person were converted into a cash payment, providing liquidity to option holders.

Negatives

• Surmodics, Inc. ceased to be an independent publicly traded company, transitioning to a wholly-owned subsidiary.
• Existing shareholders no longer hold equity in Surmodics, Inc. following the merger.
• Out-of-the-money stock options would not have yielded any cash payment upon conversion.

Risks

• No specific risks are detailed in this report, which primarily documents the outcome of a completed merger transaction.

Future Outlook

No forward-looking statements or guidance are provided, as this report details a completed merger transaction.

Management Comments

• Actions taken by company management, specifically the Chief Financial Officer, are detailed, showing the conversion of equity holdings into cash in accordance with the Merger Agreement.

Industry Context

This merger represents a consolidation event within the medical device or life sciences industry, where Surmodics operates. Such acquisitions often occur as larger entities seek to expand market share, acquire technology, or achieve synergies. The specific impact on industry trends would depend on the strategic rationale of BCE Parent, LLC's acquisition.

Comparison to Industry Standards

• Not applicable, as this report details a specific insider transaction following a merger, rather than operational or financial performance metrics that would typically be benchmarked against industry standards.

Management Changes

Corporate Governance

Legal Proceedings

• No legal or regulatory matters are mentioned.

Related Party Transactions

• No related party dealings are disclosed beyond the merger itself, which involved Surmodics, Inc. becoming a subsidiary of BCE Parent, LLC.

Stakeholder Impact

• Shareholders: Received $43.00 per share in cash for their common stock, providing liquidity and a definitive return on investment.
• Employees (including the CFO): Equity compensation (RSUs and stock options) was converted into cash, providing a payout for vested and in-the-money holdings.
• Company: Surmodics, Inc. ceased to be an independent public entity, becoming a wholly-owned subsidiary of BCE Parent, LLC.

Next Steps

• No further actions or milestones are mentioned for Surmodics, Inc. as it is now a wholly-owned subsidiary.
• The reporting person no longer holds beneficial ownership in the company.

Key Dates

Keywords

Surmodics, SRDX, Merger, Acquisition, Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Cash Consideration, BCE Parent LLC, Timothy J. Arens, CFO